Pharma's big price gouge
After Martin Shkreli raised the price of anti-HIV drugDaraprim more than 50-fold to $US750 a pill, he said he wasn't alone in taking big price hikes.
Abbott buys Alere, medical test maker, for $US5.8b
Abbott has agreed to acquire Alere for an expected value of $US5.8 billion to enhance its diagnostics business.
Healthe delays not a reason to throw a sickie
Two months after private equity firm Archer Capital said it had sold Healthe Care to China's Luye Medical for $938 million the deal has yet to settle.
Nanosonics boosts sales, but costs could delay maiden profit
Investors in Nanosonics cheered a record sales result but at least one analyst has scaled back his expectations for a maiden profit.
Ley's attack on health premiums favours big funds, threatens non-profits
Health Minister Sussan Ley's crackdown on health insurance premiums threatens the viability of smaller non-profit funds and may force industry consolidation.
Blackmores doesn't care for Nature's Care as shares come off boil
Vitamins group Blackmores says it won't be in the running to buy smaller rival Nature's Care, which could fetch up to $1 billion in a trade ...
Why investors hate Medibank
Despite two positive earnings surprises in less than six months, Medibank Private remains one of the most hated large-cap stocks on the ASX.
Radek Sali hires Goldman's Gregory to set up investment office
Goldman Sachs investment banker Adam Gregory is leaving the bank to set up an investment office backed by long-time client and vitamins comp...
Government urges health funds to sharpen pencils on premiums
Support for private health insurers has risen to its highest in two decades as not-for-profit funds threaten to campaign against reforms pla...
Healthcare not such a safe place for investors
Healthcare offers the double whammy - a safe haven in times of volatility and a great growth profile - but the threat of government cuts is ...
